Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.78 |
| ▸ | DRD2 | P14416 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.68 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.64 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5542427 | 0.91 | SIGMAR1 (0.79) | HTR1ADRD2SIGMAR1 | |
| SCHEMBL5539987 | 0.89 | SIGMAR1 (0.80) | HTR1ADRD2SIGMAR1 | |
| SCHEMBL6509439 | 0.88 | DRD2 (1.00) | HTR1ADRD2MAPTNPSR1SIGMAR1 | |
| SCHEMBL5541433 | 0.88 | SIGMAR1 (0.78) | HTR1ADRD2SIGMAR1 | |
| SCHEMBL5541878 | 0.88 | SIGMAR1 (0.78) | HTR1ADRD2SIGMAR1 | |
| SCHEMBL188941 | 0.83 | DRD4 (0.77) | HTR1ADRD2SIGMAR1 | |
| SCHEMBL28668660 | 0.83 | DRD2 (0.71) | HTR1ADRD2MAPTNPSR1SIGMAR1 | |
| SCHEMBL20765517 | 0.83 | HTR1A (0.71) | HTR1ADRD2MAPTNPSR1SIGMAR1 | |
| SCHEMBL7977889 | 0.81 | HTR1A (0.78) | HTR1ADRD2MAPTNPSR1SIGMAR1 | |
| SCHEMBL2766366 | 0.81 | HTR1A (0.78) | HTR1ADRD2MAPTNPSR1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102532162-B | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMA CO LTD | 2015-05-27 | — | — | CN | disclosed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| CN-1705670-A | 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds | OTSUKA PHARMA CO LTD (JP) | 2005-12-07 | — | — | CN | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | HTR1A 4141/4885DRD2 542/4885MAPT 4117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.